Neumora Therapeutics, Inc. (NMRA)
NASDAQ: NMRA · IEX Real-Time Price · USD
9.19
-0.58 (-5.94%)
At close: May 10, 2024, 4:00 PM
9.18
-0.01 (-0.11%)
After-hours: May 10, 2024, 7:35 PM EDT
Neumora Therapeutics Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for NMRA stock have an average target of 23.8, with a low estimate of 18 and a high estimate of 31. The average target predicts an increase of 158.98% from the current stock price of 9.19.
Analyst Consensus: Strong Buy
* Price targets were last updated on Mar 28, 2024.
Analyst Ratings
The average analyst rating for NMRA stock from 6 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 | May '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 6 | 6 | 6 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| RBC Capital | RBC Capital | Buy Reiterates $31 | Buy | Reiterates | $31 | +237.32% | Mar 28, 2024 |
| JP Morgan | JP Morgan | Buy Maintains $20 → $22 | Buy | Maintains | $20 → $22 | +139.39% | Mar 18, 2024 |
| RBC Capital | RBC Capital | Buy Maintains $24 → $31 | Buy | Maintains | $24 → $31 | +237.32% | Mar 8, 2024 |
| JP Morgan | JP Morgan | Buy Maintains $21 → $20 | Buy | Maintains | $21 → $20 | +117.63% | Nov 8, 2023 |
| JP Morgan | JP Morgan | Buy Initiates $21 | Buy | Initiates | $21 | +128.51% | Oct 10, 2023 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-1.53
from -3.63
EPS Next Year
-1.66
from -1.53
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | n/a | n/a | 99.7M | 369.4M | 706.2M |
| Avg | n/a | n/a | 32.0M | 268.9M | 529.5M |
| Low | n/a | n/a | 9.8M | 172.0M | 358.3M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | 1,055.7% | 162.6% |
| Avg | - | - | - | 741.4% | 96.9% |
| Low | - | - | - | 438.1% | 33.2% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -1.45 | -1.48 | -1.60 | -1.45 | -0.70 |
| Avg | -1.53 | -1.66 | -2.48 | -1.41 | -0.68 |
| Low | -1.71 | -1.80 | -4.01 | -1.35 | -0.66 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | - |
| Avg | - | - | - | - | - |
| Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.